Clinical Education InitiativeMenu
Search
Home > Courses > What Is It with HIV-2?

What Is It with HIV-2?

What Is It with HIV-2?
What Is It with HIV-2?
Play
Sorry, this learning module is not available for mobile devices.
Resource ID: CM360
Original Presentation: 11/11/2014
Web Posting: 3/30/2015
CE Expiration: 11/11/2017
Presenter
  • François Clavel, MD
    Head, Virus Genetics and Pathogenesis Laboratory
    French Institute of Health and Medical Research, Hôpital Saint Louis, Paris, FR
Learning Objectives
At the completion of this educational session, participants will:
  1. Understand the main genetic and pathogenic differences between HIV-1 and HIV-2.
  2. Appreciate the potential host- and virus-related mechanisms through which HIV-2 replication may be restricted in humans, making HIV-2 an interesting model for studying HIV pathogenesis.
  3. Know how HIV-2 infection is diagnosed, managed and treated.
Presenter Bio
François Clavel, MD
François Clavel received his M.D. from Necker Medical School in Paris, France. After his residency, he moved to Institut Pasteur where he was involved in the discovery and early characterization of HIV-2. He subsequently worked at NIH, went back to Institut Pasteur and started his own lab at Hôpital Bichat in Paris. He is now head of the Viral Genetics and Pathogenesis Unit at Hôpital Saint Louis, Paris. François Clavel has always been interested in virus genetics, virus evolution and virus fitness. He has spent many years describing the mechanisms of selection and evolution of HIV drug resistance. More recently, his lab has worked on HIV evolution in response to immune pressure and in response to host-specific antiviral barriers.
Continuing Education Credit

This CME activity was approved for AMA PRA Category 1 Credit™ on November 11, 2014 and will terminate November, 2017.

The target audience is all physicians, NPs and PAs involved or interested in HIV education.

This online video and post-activity evaluation are one hour in length. 

  • After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz. 
  • You must achieve at least 70% correct to receive your CME certificate. 
  • If successful, you will be provided instructions to print your CME certificate at the completion of this activity. 

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with extent of their participation in the activity.

Disclosure Statement 

Policies and standards of MSSNY require that speakers and planners for CME activities disclose any relevant financial relationships they may have with commercial interests whose products, devices or services may be discussed in the content of a CME activity.  

  • Dr. James Braun (Planner/Course Director) had no relevant financial relationships to disclose. 
  • Dr. Clavel (Presenter) had no relevant financial relationships to disclose. Dr. Clavel supported his presentation and clinical recommendations with the best available evidence from the medical literature, and submitted his slides in advance for adequate peer review.

Financial Support

This meeting of the Physicians’ Research Network (PRN) and enduring material were funded in part by educational grants from: Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Merck & Co, and ViiV Healthcare.

PRN Learning Modules